Metraipolis › archive › dc_226b2f17e552

Prodigiosin in glioblastoma: mechanistic pharmacology and rationale for its development as a radiosensitiser — Europe PMC PMID:42453580

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42453580
DOI
10.3389/fphar.2026.1767203
License (as archived)
solo-consultazione
Archived
2026-10-18T14:46:00.543Z
SHA-256 of the archived text
b4b22cbcb0df896017f46149fac81e038f2f2b60ab2c2fa1c8347580fbaa9020
Stable URL of this page
https://metraipolis.com/documento/dc_226b2f17e552

How to cite

Prodigiosin in glioblastoma: mechanistic pharmacology and rationale for its development as a radiosensitiser — Europe PMC PMID:42453580 — Europe PMC (en), https://europepmc.org/article/MED/42453580 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_226b2f17e552 (Metraipolis archive dc_226b2f17e552, sha256 b4b22cbcb0df896017f46149fac81e038f2f2b60ab2c2fa1c8347580fbaa9020)
BibTeX
@misc{dc226b2f17e552,
  title = {Prodigiosin in glioblastoma: mechanistic pharmacology and rationale for its development as a radiosensitiser — Europe PMC PMID:42453580},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42453580},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_226b2f17e552; sha256 b4b22cbcb0df896017f46149fac81e038f2f2b60ab2c2fa1c8347580fbaa9020},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42453580. Agents can read the archived copy with the MCP tool read_document.